









Markets
/
Stocks
/
nasdaq-cntb
/

Connect Biopharma Holdings Ltd

CNTB

2.900USD

-0.550-15.94%

Close 03/30, 16:00（ET）Quotes delayed by 15 min

161.87MMarket Cap

LossP/E TTM



Connect Biopharma Holdings Ltd

2.900

-0.550-15.94%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Connect Biopharma Holdings Ltd

Currency: USD Updated: 2026-03-27

Key Insights

Connect Biopharma Holdings Ltd's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered undervalued, ranking 98 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 7.90.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Connect Biopharma Holdings Ltd's Score

Industry at a Glance

Industry Ranking

98 / 391

Overall Ranking

213 / 4542

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

Connect Biopharma Holdings Ltd Highlights

StrengthsRisks

Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company. The Company is focused on advancing rademikibart, a potentially best-in-class next generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD). Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. The Company has completed a global Phase II trial (CBP-201-WW001) of rademikibart in adult patients with moderate-to-severe AD.

Growing

The company is in a growing phase, with the latest annual income totaling USD 26.03M.

Undervalued

The company’s latest PE is -3.88, at a low 3-year percentile range.

Held by James Simons

Star Investor James Simons holds 143.10K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.04.

Analyst Rating

Based on 5 analysts

Buy

Current Rating

7.900

Target Price

+114.09%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of Connect Biopharma Holdings Ltd is 6.54, ranking 236 out of 391 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.54

Change



Financials

8.82

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.68

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.84

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.26

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.08

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Connect Biopharma Holdings Ltd's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of Connect Biopharma Holdings Ltd is 6.57, ranking 251 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -3.88, which is -69.95% below the recent high of -1.17 and -6.96% above the recent low of -4.15.

Score

Industry at a Glance

Previous score

6.57

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 98/391

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

The current earnings forecast score of Connect Biopharma Holdings Ltd is 8.80, ranking 51 out of 391 in the Biotechnology & Medical Research industry. The average price target is 7.50, with a high of 10.00 and a low of 6.00.

Score

Industry at a Glance

Previous score

8.80

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 5 analysts

Buy

Current Rating

7.900

Target Price

+128.99%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

548

Total

Median

Average

Company name

Ratings

Analysts

Connect Biopharma Holdings Ltd

CNTB

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

110

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of Connect Biopharma Holdings Ltd is 9.38, ranking 10 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 4.06 and the support level at 2.61, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.79

Change

-0.41

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.089

Buy

RSI(14)

50.597

Neutral

STOCH(KDJ)(9,3,3)

53.704

Sell

ATR(14)

0.340

High Vlolatility

CCI(14)

12.289

Neutral

Williams %R

73.016

Sell

TRIX(12,20)

0.942

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

3.306

Sell

MA10

3.054

Sell

MA20

2.860

Buy

MA50

2.676

Buy

MA100

2.525

Buy

MA200

2.090

Buy

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Connect Biopharma Holdings Ltd is 3.00, ranking 195 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 44.06%, representing a quarter-over-quarter decrease of 15.05%. The largest institutional shareholder is James Simons, holding a total of 143.10K shares, representing 0.26% of shares outstanding, with 23.91% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Panacea Venture

12.00M

-13.98%

BioFortune Inc

6.16M

Shanghai Minhui Enterprise Management Consulting Partnership

5.31M

Wei (Zheng)

5.23M

-11.83%

Qiming Venture Partners

4.84M

Advantech Capital II L.P.

4.76M

Lilly Asia Ventures

3.34M

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. No risk assessment score is currently available for Connect Biopharma Holdings Ltd. The Biotechnology & Medical Research industry's average is 3.38. The company's beta value is -0.25. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.